Develop and commercialize Haduvio, an oral extended-release formulation of nalbuphine. Conduct Phase IIb/III clinical trials for Haduvio in chronic pruritus. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
Executives buying with their own money is usually read as confidence in the company’s future.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit indicators sit around the sector average.
Debt is low and cash is strong; the finances stand solid.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
Growth: Sales growth trails the sector average.
The stock trades 18% below its peak. The market has trimmed its expectations for the company.
There is $188.3M in the vault; even if every debt were paid off, $187.5M would remain.
Over the last 12 months, company executives reported 22 buys and 9 sells. Management buying with its own money is usually read as a good sign.
A loss of $42.8M against $0 in annual sales.
The growth engine is running at low revs right now. Report-card grade: 43/100.
As the slice kept from each sale thins out, so does the profit.
On our five-subject report card, TRVI sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: TRVI is a high-risk stock — not yet profitable, and its future rides on its product catching on.
Analysts’ average target sits above today’s price, yet the valuation grade (54/100) says the stock isn’t cheap.
Not covered, because the filings we hold do not carry it: the revenue breakdown.